Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma.
beta blocker
hypertriglyceridaemia
infantile hemangioma
propranolol
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
04
05
2021
accepted:
04
07
2021
pubmed:
23
7
2021
medline:
9
3
2022
entrez:
22
7
2021
Statut:
ppublish
Résumé
We present a case of a one-month-old female patient with severe hypertriglyceridaemia as a side effect of treating an ulcerating infantile hemangioma with systemic propranolol. The remarkedly rapid increase in triglyceride returned to normal 96 hours after the discontinuation of the medication, and further follow-up revealed normalisation of the lipid profile. Further research is necessary to unveil the association of systemic propranolol with hypertriglyceridaemia.
Substances chimiques
Adrenergic beta-Antagonists
0
Propranolol
9Y8NXQ24VQ
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e580-e581Informations de copyright
© 2021 Australasian College of Dermatologists.
Références
Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr. Dermatol. 2008; 25: 168-73.
Cheng CE, Friedlander SF. Infantile hemangiomas, complications and treatments. Semin. Cutan. Med. Surg. 2016; 35: 108-16.
de Graaf M, Breur JMPJ, Raphaël MF et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J. Am. Acad. Dermatol. 2011; 65: 320-7.
Basel-Vanagaite L, Zevit N, Zahav A et al. Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. Am. J. Hum. Genet. 2012; 90: 49-60.
Fogari R, Zoppi A, Corradi L et al. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 1999; 33: 534-9.